UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) announces the release of its fourth quarter and full year 2020 financial results on March 18, 2021, before market opening. This will be followed by a live audio webcast and conference call at 8:30 AM ET. UroGen is focused on innovative solutions for specialty cancers and urologic diseases, with its first commercial product, UGN-102, aimed at treating low-grade non-muscle invasive bladder cancer. The company utilizes its proprietary RTGel™ technology to enhance drug efficacy through sustained release in the urinary tract.

Positive

• Scheduled release of fourth quarter and full year 2020 financial results indicates ongoing business activity.
• UroGen's innovative RTGel™ technology may improve treatment options for bladder cancer patients.

Negative

• None.

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.

Audio Webcast
The webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

Dial-In Information
Live (U.S. / Canada): (855) 765-5685
Live (International): (615) 247-5916
Confirmation number: 9043018

About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005260/en/

FAQ

When will UroGen Pharma release its 2020 financial results?

UroGen Pharma will report its fourth quarter and full year 2020 financial results on March 18, 2021.

What is UGN-102?

UGN-102 is an investigational treatment for low-grade non-muscle invasive bladder cancer developed by UroGen.

What time is the UroGen Pharma conference call?

The conference call will be held at 8:30 AM Eastern Time on March 18, 2021.

How can I access the UroGen Pharma audio webcast?

The audio webcast can be accessed on the Investors section of UroGen's website.

What technology does UroGen Pharma utilize for its treatments?

UroGen Pharma uses RTGel™, a proprietary sustained release hydrogel-based technology to enhance therapeutic profiles.